Furthermore, targeting BCR signaling pathways by siRNA molecules or kinases inhibitors in vitro induces downregulation of anti-apoptotic protein myeloid cell leukemia 1 (MCL1) and consequently CLL B-cells apoptosis [26–28]. This evidence concerns the gene BCR and B-cell chronic lymphocytic leukemia.